Proof-of-concept Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Phase 2
16
about 9 months
18–65
10 sites in CO, IA, MA +6
About this study
This trial is testing a treatment called SION-719 when added to Trikafta in people with cystic fibrosis. The goal is to see if this new treatment is safe and well-tolerated, how it works in the body (pharmacokinetics), and how it affects the body (pharmacodynamics).
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo-to-match SION-719
- 2.Take SION-719
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed Trikafta
Secondary: Change from baseline in sweat chloride levels
Respiratory